DK3411031T3 - Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser - Google Patents
Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser Download PDFInfo
- Publication number
- DK3411031T3 DK3411031T3 DK17748198.3T DK17748198T DK3411031T3 DK 3411031 T3 DK3411031 T3 DK 3411031T3 DK 17748198 T DK17748198 T DK 17748198T DK 3411031 T3 DK3411031 T3 DK 3411031T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- preparations
- therapy
- methods
- deuterated domperidone
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical class C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291198P | 2016-02-04 | 2016-02-04 | |
| PCT/US2017/016334 WO2017136617A1 (en) | 2016-02-04 | 2017-02-03 | Deuterated domperidone compositions and methods for therapy of disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3411031T3 true DK3411031T3 (da) | 2024-10-21 |
Family
ID=59501077
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17748198.3T DK3411031T3 (da) | 2016-02-04 | 2017-02-03 | Deutererede domperidonpræparater og fremgangsmåder til terapi af lidelser |
| DK18743261.2T DK3644995T3 (da) | 2016-02-04 | 2018-06-28 | Deutererede domperidon-sammensætninger, fremgangsmåder og fremstilling |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18743261.2T DK3644995T3 (da) | 2016-02-04 | 2018-06-28 | Deutererede domperidon-sammensætninger, fremgangsmåder og fremstilling |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10266516B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3411031B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7296185B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR102851614B1 (cg-RX-API-DMAC10.html) |
| CN (4) | CN108697700B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017213852B2 (cg-RX-API-DMAC10.html) |
| BR (2) | BR112018016032B1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3055777A1 (cg-RX-API-DMAC10.html) |
| DK (2) | DK3411031T3 (cg-RX-API-DMAC10.html) |
| EA (2) | EA035515B1 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2017136617A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CN108697700B (zh) * | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
| US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US12478612B2 (en) | 2017-06-30 | 2025-11-25 | Cindome Pharma, Inc. | Deuterated domperidone compositions, methods, and preparation |
| US20210260055A1 (en) * | 2018-06-21 | 2021-08-26 | Dermavant Sciences GmbH | Topical formulations of dgat1 inhibitors and their methods of use |
| KR20210082480A (ko) * | 2018-10-25 | 2021-07-05 | 신돔 파마, 인크. | 돔페리돈을 함유하는 제제 |
| SG11202103284QA (en) * | 2018-10-25 | 2021-05-28 | Cindome Pharma Inc | Formulations containing deuterated domperidone |
| US20220307004A1 (en) * | 2021-03-29 | 2022-09-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling |
| US20250268884A1 (en) * | 2022-04-20 | 2025-08-28 | Cindome Pharma, Inc. | Deuterated Domperidone for Treating Gastroparesis |
| IL322534A (en) * | 2023-03-23 | 2025-10-01 | Cindome Pharma Inc | Methods for treating diabetic gastroparesis |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4066772A (en) | 1975-07-21 | 1978-01-03 | Janssen Pharmaceutica N.V. | 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds |
| NZ181256A (en) * | 1975-07-21 | 1978-04-28 | Janssen Pharmaceutica Nv | 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives |
| TW466119B (en) * | 1994-02-28 | 2001-12-01 | Janssen Pharmaceutica Nv | Film coated tablet of paracetamol and domperidone |
| FR2725986B1 (fr) * | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US20140271788A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US20140070440A1 (en) | 2001-10-12 | 2014-03-13 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20140163060A1 (en) | 2001-10-12 | 2014-06-12 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20130220526A1 (en) | 2001-10-12 | 2013-08-29 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| US20160206639A9 (en) | 2001-10-12 | 2016-07-21 | Monosol Rx, Llc | Films and Drug Delivery Systems Made Therefrom |
| ITMI20020514A1 (it) | 2002-03-12 | 2003-09-12 | Jagotec Ag | Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| CN1688294A (zh) | 2002-10-01 | 2005-10-26 | 旗帜药物胶囊公司 | 用于制备软胶囊壁的肠溶组合物 |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| CA2858733C (en) | 2004-12-31 | 2017-12-19 | Iceutica Pty Ltd | Nanoparticle compositions and methods for synthesis thereof |
| ITMI20050477A1 (it) | 2005-03-23 | 2006-09-24 | Bouty S P A | Cerotto transdermico |
| CN100435795C (zh) * | 2006-02-27 | 2008-11-26 | 南京长澳医药科技有限公司 | 一种微粉化马来酸多潘立酮药物组合物及其制备方法 |
| CN100386323C (zh) * | 2006-02-27 | 2008-05-07 | 南京长澳医药科技有限公司 | 马来酸多潘立酮的合成方法 |
| US8846100B2 (en) | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
| NZ573823A (en) | 2006-06-30 | 2012-05-25 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| CA2685362A1 (en) | 2007-04-26 | 2008-11-06 | Craig A. Aronchick | Compositions and methods for transmucosal delivery of domperidone |
| MX2010001789A (es) | 2007-08-15 | 2010-03-10 | Mcneil Ppc Inc | Regimen de dosificacion de ibuprofeno de liberacion inmediata y liberacion sostenida. |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090076010A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched lamotrigine |
| US20110160253A1 (en) | 2008-05-28 | 2011-06-30 | Harbeson Scott L | Deuterated tizanidine |
| US20100113405A1 (en) * | 2008-11-06 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Methylindazole modulators of 5-ht3 receptors |
| US20100120733A1 (en) * | 2008-11-07 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| NZ595985A (en) | 2009-04-24 | 2014-07-25 | Iceutica Pty Ltd | A novel formulation of naproxen |
| NZ710384A (en) | 2009-04-24 | 2017-03-31 | Iceutica Pty Ltd | A novel formulation of indomethacin |
| CA2759109A1 (en) | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics |
| CA2759123C (en) | 2009-04-24 | 2019-01-15 | Iceutica Pty Ltd | Compositions of diclofenac acid with improved dissolution |
| MX360019B (es) | 2009-04-24 | 2018-10-15 | Iceutica Pty Ltd | Una formulación novedosa de metaxalona. |
| US20140017299A1 (en) | 2011-08-18 | 2014-01-16 | Monosol Rx, Llc | Steroid hormone delivery systems and methods of preparing the same |
| JP5093545B1 (ja) | 2012-02-28 | 2012-12-12 | ニチバン株式会社 | 貼付剤 |
| EP3450434B1 (en) | 2012-06-15 | 2021-02-24 | CoNCERT Pharmaceuticals, Inc. | Deuterated derivatives of ruxolitinib |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| US20140019395A1 (en) | 2012-07-12 | 2014-01-16 | Craig Charles Bauer | Method and application of Fear, Love and Methodology as protocols within and of a programming group, as a means of creating an artificial individual, software system or other independent entity capable of independent self directive creation of choice and/or self directive creation of purpose within a virtual and/or any environment |
| AU2014236597A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US20140271787A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Continuous single layer film structure including discrete domains |
| TWI686212B (zh) | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| US20140272220A1 (en) | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Reduction in stress cracking of films |
| CN108697700B (zh) | 2016-02-04 | 2021-08-17 | 辛多美制药有限公司 | 氘代多潘立酮组合物和用于治疗病症的方法 |
| US11364226B2 (en) * | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
| SG11202103284QA (en) * | 2018-10-25 | 2021-05-28 | Cindome Pharma Inc | Formulations containing deuterated domperidone |
| US20250268884A1 (en) * | 2022-04-20 | 2025-08-28 | Cindome Pharma, Inc. | Deuterated Domperidone for Treating Gastroparesis |
-
2017
- 2017-02-03 CN CN201780008640.9A patent/CN108697700B/zh active Active
- 2017-02-03 EP EP17748198.3A patent/EP3411031B1/en active Active
- 2017-02-03 EA EA201891727A patent/EA035515B1/ru not_active IP Right Cessation
- 2017-02-03 WO PCT/US2017/016334 patent/WO2017136617A1/en not_active Ceased
- 2017-02-03 DK DK17748198.3T patent/DK3411031T3/da active
- 2017-02-03 JP JP2018535888A patent/JP7296185B2/ja active Active
- 2017-02-03 AU AU2017213852A patent/AU2017213852B2/en active Active
- 2017-02-03 CN CN202111078948.5A patent/CN113995755A/zh active Pending
- 2017-02-03 KR KR1020187023566A patent/KR102851614B1/ko active Active
- 2017-02-03 BR BR112018016032-6A patent/BR112018016032B1/pt active IP Right Grant
- 2017-06-30 US US15/639,431 patent/US10266516B2/en active Active
-
2018
- 2018-06-28 BR BR112019028185A patent/BR112019028185A8/pt not_active Application Discontinuation
- 2018-06-28 CA CA3055777A patent/CA3055777A1/en active Pending
- 2018-06-28 JP JP2019571517A patent/JP7602324B2/ja active Active
- 2018-06-28 CN CN201880043378.6A patent/CN111093653B/zh active Active
- 2018-06-28 WO PCT/US2018/039928 patent/WO2019006078A1/en not_active Ceased
- 2018-06-28 AU AU2018290905A patent/AU2018290905B2/en active Active
- 2018-06-28 DK DK18743261.2T patent/DK3644995T3/da active
- 2018-06-28 EP EP18743261.2A patent/EP3644995B1/en active Active
- 2018-06-28 KR KR1020207002879A patent/KR102695402B1/ko active Active
- 2018-06-28 EA EA202090183A patent/EA202090183A1/ru unknown
- 2018-06-28 CN CN202310648870.9A patent/CN116712432A/zh active Pending
-
2019
- 2019-04-16 US US16/385,599 patent/US10590110B2/en active Active
-
2022
- 2022-12-22 JP JP2022205876A patent/JP2023052045A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3559009T3 (da) | Sammensætninger og metoder til inhibition af arginaseaktivitet | |
| DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3426781T3 (da) | Mikro-rna'er og fremgangsmåder til anvendelse deraf | |
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| DK3529257T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK4105223T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3551209T3 (da) | Insulin-fc-fusioner og fremgangsmåder til anvendelse | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK4234581T3 (da) | Terapeutiske antistoffer og deres anvendelse | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| DK4434585T3 (da) | Forbindelser og fremgangsmåder til reduktion af snca-ekspression | |
| DK3514151T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3710430T3 (da) | Acss2-inhibitorer og fremgangsmåder til anvendelse deraf | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3812392T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| IL281420A (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf |